Press Releases Year None20252024202320222021202020192018 Jan 13, 2025 Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD Jan 07, 2025 Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Year None20252024202320222021202020192018 Jan 13, 2025 Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD Jan 07, 2025 Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 13, 2025 Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
